The Biologics News and Reports Portal

Show Cart

La Merie Publishing

Results 161 - 180 of 192

Mar 2013 Influence of Antibody Attributes on Clinical Success – A Technology and Coporate Benchmark Analysis

900.00 €

Feb 2013 Competitor Analysis: FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART)

250.00 €

Oct 2012 Competitor Analysis: Interleukin-6 (IL-6) Inhibitors and IL-6 Receptor (IL-6R) Antagonists

150.00 €

Sep 2012 Competitor Analysis: Tuberculosis Vaccines and Therapeutics

400.00 €

Aug 2012 Competitor Analysis: Malaria Vaccines & Therapeutics

300.00 €

Aug 2012 Competitor Analysis: CMV Vaccines and Therapeutics

200.00 €

Jul 2012 Competitor Analysis: Interleukin-1 (IL-1) Inhibitors and IL-1 Receptor (IL-1R) Antagonists

150.00 €

May 2012 Competitor Analysis: Pseudomonas aeruginosa Vaccines and Therapeutics

300.00 €

Mar 2012 Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012

1,950.00 €

Dec 2011 Competitor Analysis: HIV Small Molecule Therapeutics

500.00 €

Nov 2011 Competitor Analysis: Anti-Infective Antibodies

400.00 €

800.00 €

(Discount: 50.00%)

Oct 2011 Coagulation Factors 2011 – who does meet the market needs? A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis

1,920.00 €

2,400.00 €

(Discount: 20.00%)

Oct 2011 Competitor Analysis: HIV Vaccines

300.00 €

Sep 2011 Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis

1,560.00 €

1,950.00 €

(Discount: 20.00%)

Sep 2011 Competitor Analysis: Novel Mitotic Kinase Inhibitors

400.00 €

Aug 2011 Competitor Analysis: Targeted Therapy of Hepatitis C

600.00 €

Shopping cart

Cart empty

Latest report

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Featured Products

Report bundle: Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Latest Target Pipeline

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Shopping cart

Cart empty

Latest report

Featured Products

Report bundle: Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Latest Target Pipeline

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

La Merie Publishing

Mar 2013 Influence of Antibody Attributes on Clinical Success – A Technology and Coporate Benchmark Analysis

Feb 2013 Competitor Analysis: FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART)

Jan 2013 Competitor Analysis: Enzyme Replacement Therapies

Dec 2012 Competitor Analysis: Herpes Virus Vaccines and Therapeutics

Dec 2012 Competitor Analysis: Toll-Like Receptor (TLR) Agonists & Antagonists

Oct 2012 Competitor Analysis: Pneumococcal and Streptococcal Vaccines

Oct 2012 Competitor Analysis: Interleukin-6 (IL-6) Inhibitors and IL-6 Receptor (IL-6R) Antagonists

Sep 2012 Competitor Analysis: Tuberculosis Vaccines and Therapeutics

Aug 2012 Competitor Analysis: Malaria Vaccines & Therapeutics

Aug 2012 Competitor Analysis: CMV Vaccines and Therapeutics

Jul 2012 Competitor Analysis: Interleukin-1 (IL-1) Inhibitors and IL-1 Receptor (IL-1R) Antagonists

May 2012 Competitor Analysis: Pseudomonas aeruginosa Vaccines and Therapeutics

Mar 2012 Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - A Target Pipeline and Stakeholder Analysis 2012

Dec 2011 Competitor Analysis: HIV Small Molecule Therapeutics

Nov 2011 Competitor Analysis: Anti-Infective Antibodies

Oct 2011 Coagulation Factors 2011 – who does meet the market needs? A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis

Oct 2011 Competitor Analysis: HIV Vaccines

Sep 2011 Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis

Sep 2011 Competitor Analysis: Novel Mitotic Kinase Inhibitors

Aug 2011 Competitor Analysis: Targeted Therapy of Hepatitis C

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

Shopping cart

Latest report

Featured Products

Latest Target Pipeline

La Merie Biologics

FREE Weekly News Bulletin

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing